Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor

GlobeNewswire March 3, 2022

Medicenna to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 10, 2022

Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights

GlobeNewswire February 9, 2022

Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022

GlobeNewswire February 2, 2022

Medicenna Announces Formation of its Scientific Advisory Board

GlobeNewswire January 31, 2022

Medicenna (TSX:MDNA) announces publication of MDNA11 preclinical data

Caroline Egan  January 26, 2022

Medicenna Announces Peer-Reviewed Publication of Preclinical Data on MDNA11 in the Journal for ImmunoTherapy of Cancer

GlobeNewswire January 26, 2022

Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee

GlobeNewswire January 17, 2022

Medicenna to Participate in Upcoming January Investor Conferences

GlobeNewswire January 5, 2022

Medicenna (TSX:MDNA) fights against cancer

Brieanna McCutcheon  December 22, 2021

Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study

GlobeNewswire December 22, 2021

Medicenna (TSX:MDNA) expands diabetes treatment study to Canada

Brieanna McCutcheon  December 17, 2021

Medicenna Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada

GlobeNewswire December 17, 2021

Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th Annual Meeting of the Society for Neuro-Oncology

GlobeNewswire November 18, 2021

Medicenna (TSX:MDNA) provides second quarter 2022 financial and operational highlights

Julia Kennedy  November 12, 2021

Medicenna Reports Second Quarter Fiscal 2022 Financial Results and Operational Highlights

GlobeNewswire November 12, 2021

Medicenna Therapeutics to Present at Stifel's Virtual Healthcare Conference

GlobeNewswire November 9, 2021

Medicenna Therapeutics to Announce Second Quarter 2022 Financial Results and Operational Highlights on Friday, November 12, 2021

GlobeNewswire November 4, 2021

Medicenna’s (TSX:MDNA) receives FDA clearance to expand MDNA11 study

Brieanna McCutcheon  October 27, 2021

Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States

GlobeNewswire October 27, 2021